Why There's Still Need for Rapid Accessible Pathogen Testing, During and After the Crisis

NEW YORK, Jan. 13, 2021 /PRNewswire/ -- As the most at-risk people begin to receive COVID-19 vaccinations, we are all looking forward to a post-pandemic world. As we transition back to something closer to normal life, however, the importance of rapid detection of any pathogen that could be hazardous to human health will not be forgotten any time soon. This crisis spurred the development of virus and pathogen technologies that are not only invaluable for rapid detection and response to pandemic viruses but also for everyday use in the medical and food safety spaces and elsewhere. Developed by companies like Lexagene Hldgs Inc. (TSX-V: LXG) (OTC: LXXGF) (FRA:5XS2), Medmira Inc. (TSX-V: MIR) (OTC: MMIRF), Co-Diagnostics Inc. (NASDAQ:CODX), 3M Co. (NYSE: MMM), and Laboratories (NYSE: ABT), these technologies could continue to be game-changing in the post-pandemic world and possibly even help prevent future health crises.

LexaGene's MiQLab Makes Testing Quick and Simple

Massachusetts-based molecular diagnostics company Lexagene Hldgs Inc. (TSX-V: LXG) (OTCQB: LXXGF) (FRA:5XS2) has developed a fully automated system that makes the process of detecting pathogens quick and remarkably simple at the point-of-need where samples are collected. The technology can be used to detect viruses like COVID-19 or others, or for other purposes such as lab testing for food safety, veterinary diagnostics, and more. The company's founder and CEO Dr. Jack Regan developed the precursor to this technology while working for the Department of Homeland Security at Lawrence Livermore National Laboratory and LexaGene holds the exclusive license to sell the commercial version.

LexaGene is calling its flagship product the MiQLab automated pathogen detection system, and the company says that the system could transform the way both human clinical diagnostics and veterinary diagnostics are conducted. The system uses multiplex testing to detect up to 27 targets at once. MiQLab is the first commercially available open-access multiplex PCR system of its kind, allowing users to receive lab-quality test results in approximately an hour at the point-of-need, without having to send samples away for testing. The system is designed for ease of use, allowing for operation by non-technical users with relatively little training required.

MiQLab is designed for versatility. The system is ideal for use in a range of industries and tests can be onboarded quickly, allowing it to test for new pathogens as they emerge. This means that in addition to having a wide range of everyday uses, MiQLab is set up to be critical during this pandemic as new COVID variants appear, such as those identified in the United Kingdom (B.1.1.7) and South Africa (B.1.351), and in the event of any new health crises that may occur in the future.

On December 30th, LexaGene announced that the company has begun a series of studies required by the FDA for Emergency Use Authorization (EUA) testing for its COVID-19 assay in a point-of-care (POC) environment using the MiQLab system. This development is notable because the majority of other testing systems that have been submitted for this designation can only be used by highly trained personnel, whereas MiQLab, with its simple usability, would allow for far faster and more accessible testing.

"I'm excited we have progressed to the point where we have started our FDA study," Dr. Regan said in the company's release. "Our open-access technology is unlike any other on the market today, as it could be configured quickly to detect new variants, such as the recent UK variant (aka SARS-CoV-2 VUI 202012/01)."

Biotech Companies Look to Develop Rapid Testing Methods

Co-Diagnostics Inc. (NASDAQ: CODX) has developed the Logix Smart COVID-19 test kit. The test uses a single step real-time reverse transcriptase polymerase chain reaction process in lower and upper respiratory tract fluids to detect the ribonucleic acid from the form SARS-CoV-2 coronavirus in patients who meet the clinical criteria for COVID-19.

3M Co. (NYSE: MMM) has been in the spotlight since the start of the pandemic for several of its medical and personal protective equipment products. In July, the company announced that it was working with the Massachusetts Institute of Technology to create an antigen test for COVID-19. The company's priority was to improve the speed, accessibility, and affordability of testing for the virus.

On December 30th, Canadian biotechnology company Medmira Inc. (TSXV: MIR) (OTC:MMIRF) unveiled an improved version of the company's REVEALCOVID-19 Total Antibody Test that Medmira claims accurately detects antibodies against both the Nucleocapsid and Spike regions of the SARS-CoV-2 virus. This test confirms the effectiveness of the Pfizer and Moderna vaccines in vaccinated individuals.

In the early months of the pandemic, Abbott Labs (NYSE: ABT) was one of the first companies to develop specialized testing for COVID-19 and receive emergency use authorization from the FDA. Today, the company markets several COVID tests, including its BinaxNOW rapid point-of-care test.

While it's tempting to look ahead to a world where COVID-19 is no longer a concern, the need for rapid testing is not going away anytime soon. This is ensuring near-term demand for products like LexaGene's MiQLab, and the system's many other applications will likely keep that demand going long after the crisis.

Click here to find out more about LexaGene.

Subscribe Now! Watch us report LIVE https://www.youtube.com/FinancialBuzzMedia 
Follow us on Twitter for real time Financial News Updates: https://twitter.com/financialbuzz 
Follow and talk to us on Instagram: https://www.instagram.com/financialbuzz 
Facebook Like Us to receive live feeds: https://www.facebook.com/Financialbuzz/

About FinancialBuzz.com 

FinancialBuzz.com, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content. FinancialBuzz.com also provides financial news PR dissemination, branding, marketing and advertising for third parties for corporate news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.

Please Note: FinancialBuzz.com is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on http://www.FinancialBuzz.com (the 'Site') is either original financial news or paid advertisements provided [exclusively] by our affiliates (sponsored content), FinancialBuzz.com, a financial news media and marketing firm enters into media buys or service agreements with the companies which are the subject to the articles posted on the Site or other editorials for advertising such companies. FinancialBuzz.com has not been compensated directly by any of the companies mentioned here in this editorial unless mentioned otherwise. Clients from time-to-time place links in FinancilBuzz.com editorials and these are strictly for informational purposes only and FinancialBuzz.com has not researched these links and are not responsible for their content. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete. FinancialBuzz.com receives fees for producing and presenting high quality and sophisticated content on FinancialBuzz.com along with other financial news PR media services. FinancialBuzz.com does not offer any personal opinions, recommendations or bias commentary as we purely incorporate public market information along with financial and corporate news. FinancialBuzz.com only aggregates or regurgitates financial or corporate news through our unique financial newswire and media platform. For Lexagene Hldgs Inc. video production, filming editing, news reporting, financial and corporate news dissemination, FinancialBuzz.com has been compensated five thousand dollars by marketjar media inc. Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this editorial or site, or a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement. FinancialBuzz.com has agreed to three hundred thousand common and restricted shares locked up for six months, FinancialBuzz.com will always disclose any compensation in securities or cash payments for financial news PR advertising. FinancialBuzz.com does not undertake to update any of the information on the editorial or Site or continue to post information about any companies the information contained herein is not intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any security. FinancialBuzz.com, members and affiliates are not responsible for any gains or losses that result from the opinions expressed on this editorial or Site, company profiles, quotations or in other materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and financial condition. FinancialBuzz.com. By accessing this editorial and website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by FinancialBuzz.com constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication is provided by FinancialBuzz.com. Each investor is solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use, please visit: http://www.financialbuzz.com.

Media Contact:
info@financialbuzz.com 
+1-877-601-1879
www.FinancialBuzz.com

Cision View original content:http://www.prnewswire.com/news-releases/why-theres-still-need-for-rapid-accessible-pathogen-testing-during-and-after-the-crisis-301207159.html

SOURCE FinancialBuzz.com

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.